Upstream Bio, Inc.
$9.99
▲
2.04%
2026-04-21 10:02:02
upstreambio.com
NMS: UPB
Explore Upstream Bio, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$543.66 M
Current Price
$9.99
52W High / Low
$33.68 / $7.25
Stock P/E
—
Book Value
$6.26
Dividend Yield
—
ROCE
-47.12%
ROE
-35.44%
Face Value
—
EPS
$-2.66
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
75
Beta
—
Debt / Equity
0.37
Current Ratio
26.15
Quick Ratio
26.15
Forward P/E
-3.25
Price / Sales
200.02
Enterprise Value
$230.63 M
EV / EBITDA
-1.44
EV / Revenue
80.81
Rating
Strong Buy
Target Price
$43.57
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Cyclerion Therapeutics, Inc. | $3 | — | $13.08 M | — | -40.99% | -39.34% | $8.48 / $1.03 | $2.38 |
| 2. | Biomea Fusion, Inc. | $2.05 | — | $159.78 M | — | -171.28% | -1.52% | $3.08 / $0.87 | $0.41 |
| 3. | Rezolute, Inc. | $3.37 | — | $322.5 M | — | -48.84% | -74.02% | $11.46 / $1.07 | $1.23 |
| 4. | Insmed Incorporated | $143.43 | — | $31.02 B | — | -55.4% | -2.49% | $212.75 / $63.81 | $3.45 |
| 5. | Kezar Life Sciences, Inc. | $7.29 | — | $53.74 M | — | -74.59% | -59.93% | $7.55 / $3.53 | $9.56 |
| 6. | BioMarin Pharmaceutical Inc. | $54.33 | 30.1 | $10.47 B | — | 5.99% | 5.94% | $66.28 / $50.76 | $31.65 |
| 7. | Acrivon Therapeutics, Inc. | $1.86 | — | $68.97 M | — | -73.75% | -53.86% | $3.56 / $1.05 | $3.56 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0.67 M | 0.68 M | 0.94 M | 0.57 M | 0.61 M | — |
| Operating Profit | -46.17 M | -37.83 M | -44.35 M | -32.01 M | -26.32 M | — |
| Net Profit | -42.46 M | -33.75 M | -39.97 M | -27.27 M | -21.24 M | — |
| EPS in Rs | -0.78 | -0.62 | -0.73 | -0.5 | -0.39 | -0.41 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 2.85 M | 2.37 M | 2.38 M | 1.21 M |
| Operating Profit | -160.36 M | -77.76 M | -40.11 M | -23.91 M |
| Net Profit | -143.44 M | -62.81 M | -20.54 M | -23.87 M |
| EPS in Rs | -2.64 | -1.15 | -0.38 | -0.44 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 353.77 M | 481.72 M | 117.2 M | 18.48 M |
| Total Liabilities | 14 M | 11.87 M | 240.32 M | 124.63 M |
| Equity | 339.77 M | 469.85 M | -123.13 M | -106.16 M |
| Current Assets | 351.8 M | 479.16 M | 117 M | 18.31 M |
| Current Liabilities | 13.45 M | 10.74 M | 6.51 M | 4.86 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -133.28 M | -59.17 M | -37.93 M | -19.02 M |
| Investing CF | -93.48 M | -59.48 M | -82.84 M | -0.08 M |
| Financing CF | 2.44 M | 418.91 M | 129.55 M | 9.96 M |
| Free CF | -133.44 M | -59.68 M | -38.07 M | -19.1 M |
| Capex | -0.17 M | -0.51 M | -0.14 M | -0.08 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | 20.42% | -0.42% | 96.37% | — |
| Earnings Growth % | -128.39% | -205.82% | 13.96% | — |
| Profit Margin % | -5026.03% | -2650.04% | -862.9% | -1969.31% |
| Operating Margin % | -5618.82% | -3281.18% | -1685.46% | -1972.69% |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -5612.23% | -3277.43% | -1682.94% | -1972.11% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.